MARK RICHARD J sold (to issuer) $86K of THC

MARK RICHARD J sold (to issuer) 493 shares of TENET HEALTHCARE CORP (THC) at $173.78 on 2026-05-22.

Original reporting
SEC EDGAR · MARK RICHARD J
Published May 27, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
medium confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

Traders may briefly reassess sentiment around management confidence, but without accompanying company fundamentals (earnings, guidance, litigation, contracts), the expected impact is limited.

02

Market read

A single insider sale disclosure for THC, with modest sentiment sensitivity due to non-10b5-1 labeling, but no fundamental catalyst mentioned.

03

What to watch

The absence of a 10b5-1 plan can increase perceived signal, but the article lacks context on why the sale occurred (tax, diversification, or corporate buyback participation).

Relevance 6/10Timing: Immediate (filed 2026-05-26; trade dated 2026-05-22) but typically limited follow-through.

Background

SEC Form 4 reports insider transactions by directors/officers; this filing shows a director sale to the issuer at a specific price and date.

Company-level read

Ticker impact

$THCNeutralMedium confidence
Context

Tenet Healthcare director Mark Richard J sold 493 shares to the issuer for $173.78/share, disclosed via SEC Form 4 on 2026-05-26.

Expected impact

Low near-term impact; any reaction is likely limited to intraday sentiment around insider activity.

Evidence & confidence

The filing provides transaction size, price, and that it was not under a pre-arranged 10b5-1 plan, but it does not cite earnings, guidance, or operational changes.

Market effects

Minimal—no sector-wide catalyst is described beyond a single-company insider transaction.

None indicated; the filing is company-specific.

None indicated; no international or cross-border transaction details are provided.

Counterpoint

Because the sale is coded as “sale to issuer,” it may reflect routine liquidity/plan mechanics tied to corporate actions rather than a bearish view.

Key entities

  • Tenet Healthcare Corp

    Company whose director insider transaction was disclosed on SEC Form 4 (THC).

  • Mark Richard J

    Director who sold 493 shares to the issuer for $85,673.54; trade not stated as 10b5-1.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$THCHighAI 8/10

Mizuho raises Tenet Healthcare stock price target on strong results

Mizuho increased its price target for Tenet Healthcare (NYSE:THC) to $305 from $290, citing strong quarterly results and raised 2026 EBITDA estimates. The stock trades near its 52-week high after a 49% six-month surge. Tenet reported Q3 2026 EPS of $6.64, beating estimates, and raised its full-year EBITDA outlook. Guggenheim maintained a Buy rating with a slightly lowered target of $306.

$THCMed

Tenet Healthcare Q3 Earnings Call Highlights

Tenet Healthcare (THC) reported Q3 earnings, with hospital segment showing 3.2% growth in admissions and 11% adjusted EBITDA increase. Revenue per admission rose 0.2% YoY. Exchange admissions and revenues declined 18%. Conifer transition activities contributed $147M, with $450M expected in 2026. Tenet generated $1.1B in adjusted free cash flow and repurchased 970K shares.